Alpelisib
Especificaciones
1217486-61-7Número CAS
806-598-7Número CE
(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamideNombre IUPAC
C19H22F3N5O2SFórmula química
441.5 g/molPeso molecular
alpelisib; 1217486-61-7; BYL-719; BYL719; Piqray; NVP-BYL719; Vijoice; BYL 719; 08W5N2C97Q; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; 1,2-Pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2S)-; 1,2-PYRROLIDINEDICARBOXAMIDE, N1-[4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL]-2-THIAZOLYL]-, (2S)-; DTXSID70153355; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide; alpelisibum; (2S)-1-N-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)-1,3-thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; (2S)-1-N-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl]thiazol-2-yl]amide; RefChem:57062; DTXCID7075846; L01XX65; Phosphoinositide 3-kinase Inhibitor BYL719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; UNII-08W5N2C97Q; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; Alpelisib [USAN:INN]; MFCD22417085; CHEMBL2396661; (2s)-N~1~-{4-Methyl-5-[2-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)pyridin-4-Yl]-1,3-Thiazol-2-Yl}pyrrolidine-1,2-Dicarboxamide; (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.; Alpelisib [INN]; C19H22F3N5O2S; A lpelisib; 4jps; 1LT; Alpelisib [USAN]; Vijoice (TN); Piqray (TN); ALPELISIB [JAN]; ALPELISIB [MI]; ALPELISIB [WHO-DD]; Alpelisib (JAN/USAN/INN); GTPL7955; orb1226776; orb1307105; SCHEMBL1911869; ALPELISIB [ORANGE BOOK]; SCHEMBL29358059; CHEBI:93752; EX-A405; STUWGJZDJHPWGZ-LBPRGKRZSA-N; BDBM738244; BYL 719; BYL719; GLXC-90284; BDBM50436459; EBC-11472; NSC765974; NSC800065; s2814; AKOS022186315; CCG-269139; CS-0663; DB12015; FP71607; NSC-765974; NSC-800065; SDCCGSBI-0654479.P001; US20250145589, Example Alpelisib; NCGC00346717-03; NCGC00346717-06; NCGC00346717-09; NCGC00346717-12; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine; (2S)-N1-{4-METHYL-5-[2-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL]-1,3-THIAZOL-2-YL}PYRROLIDINE-1,2-DICARBOXAMIDE; AC-37083; AS-16349; HY-15244; B9700; NS00072895; SW220128-1; cas:1217486-61-7;BYL-719; D11011; EN300-23810842; BRD-K54997624-001-06-0; Q27074391; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-4-pyridyl]thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2S)-N1-{4-Methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide; BYL-719A-1214(S)-N1-(4-METHYL-5-(2-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL)THIAZOL-2-YL)PYRROLIDINE-1,2-DICARBOXAMIDESinónimos
Productos que contienen Alpelisib
피크레이정50밀리그램(알펠리십), 피크레이정150밀리그램(알펠리십), 피크레이정200밀리그램(알펠리십)PIQRAY 50 MG y 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 50 mg et 200 mg, comprimé pelliculéPIQRAY 200 mg, comprimé pelliculéPIQRAY 150 mg, comprimé pelliculéAlpelisib - ArevipharmaAlpelisib - Novartis Pharmaceuticals CorporationAlpelisibAlpelisibAlpelisib
